Data_Sheet_2_Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.docx
Background: PI3K/AKT signaling pathway is activated in breast cancer and associated with cell survival. We explored the prevalence of PI3K pathway alterations and co-expression with other markers in breast cancer subtypes.
Methods: Samples of non-matched primary and metastatic breast cancer submitted to a CLIA-certified genomics laboratory were molecularly profiled to identify pathogenic or presumed pathogenic mutations in the PIK3CA-AKT1-PTEN pathway using next generation sequencing. Cases with loss of PTEN by IHC were also included. The frequency of co-alterations was examined, including DNA damage response pathways and markers of response to immuno-oncology agents.
Results: Of 4,895 tumors profiled, 3,558 (72.7%) had at least one alteration in the PIK3CA-AKT1-PTEN pathway: 1,472 (30.1%) harbored a PIK3CA mutation, 174 (3.6%) an AKT1 mutation, 2,682 (54.8%) had PTEN alterations (PTEN mutation in 7.0% and/or PTEN loss by IHC in 51.4% of cases), 81 (1.7%) harbored a PIK3R1 mutation, and 4 (0.08%) a PIK3R2 mutation. Most of the cohort consisted of metastatic sites (n = 2974, 60.8%), with PIK3CA mutation frequency increased in metastatic (32.1%) compared to primary sites (26.9%), p < 0.001. Other PIK3CA mutations were identified in 388 (7.9%) specimens, classified as “off-label,” as they were not included in the FDA-approved companion test for PIK3CA mutations. Notable co-alterations included increased PD-L1 expression and high tumor mutational burden in PIK3CA-AKT1-PTEN mutated cohorts. Novel concurrent mutations were identified including CDH1 mutations.
Conclusions: Findings from this cohort support further exploration of the clinical benefit of PI3K inhibitors for “off-label” PIK3CA mutations and combination strategies with potential clinical benefit for patients with breast cancer.
History
References
- https://doi.org//10.18632/oncotarget.25118
- https://doi.org//10.1016/j.canlet.2005.11.042
- https://doi.org//10.1038/nrc1819
- https://doi.org//10.1146/annurev.cellbio.17.1.615
- https://doi.org//10.1002/prot.22265
- https://doi.org//10.1073/pnas.0712169105
- https://doi.org//10.1038/nrd2926
- https://doi.org//10.1016/j.advenzreg.2006.01.004
- https://doi.org//10.18632/oncotarget.21914
- https://doi.org//10.1016/j.ejmech.2019.111718
- https://doi.org//10.1038/nature13948
- https://doi.org//10.1056/NEJMoa1813904
- https://doi.org//10.1593/neo.131694
- https://doi.org//10.1007/s10549-018-4697-y
- https://doi.org//10.1002/ijc.30834
- https://doi.org//10.1158/1078-0432.CCR-17-2260
- https://doi.org//10.1007/s10637-017-0433-4
- https://doi.org//10.3892/ijo.2015.3062
- https://doi.org//10.1158/2159-8290.CD-11-0348
- https://doi.org//10.1093/annonc/mdw672
- https://doi.org//10.1158/1078-0432.CCR-16-0134
- https://doi.org//10.1158/1535-7163.MCT-15-0143
- https://doi.org//10.1016/j.eururo.2014.08.006
- https://doi.org//10.1016/j.ccr.2014.05.020
- https://doi.org//10.1200/PO.19.00049
- https://doi.org//10.3389/fonc.2019.01289
- https://doi.org//10.1016/j.breast.2018.08.002
- https://doi.org//10.1158/1538-7445.AM2019-CT049
- https://doi.org//10.1043/1543-2165-134.7.e48
- https://doi.org//10.1200/JCO.2009.25.6529
- https://doi.org//10.1200/JOP.18.00206
- https://doi.org//10.1200/JCO.2013.50.9984
- https://doi.org//10.1002/cam4.1372
- https://doi.org//10.1056/NEJMoa1801946
- https://doi.org//10.1186/s13058-020-01284-9
- https://doi.org//10.1158/0008-5472.CAN-15-1654
- https://doi.org//10.1016/S1470-2045(17)30450-3
- https://doi.org//10.1200/JCO.19.00368
- https://doi.org//10.1038/ncomms11908
- https://doi.org//10.1158/1538-7445.SABCS16-PD8-04
- https://doi.org//10.1093/annonc/mdy024
- https://doi.org//10.1016/S1470-2045(19)30689-8
- https://doi.org//10.1158/1538-7445.AM2018-2986